Aurinia Pharmaceuticals Inc (AUPH)

[moosedogger]

Additional excerpts from borrowed Cowen report:

AUPH
from Cowen: it appears the treatment population could be anywhere between roughly 60-80,000 patients, and the survey indicates – as noted above – that the clinicians plan on treating roughly 45% of their patients with voclosporin within three years (or roughly 25-35,000 patients) which would be nearly double the 15-20,000 LN patient target that is necessary to reach our $1B peak estimate.

30k at $60k = 1.8 billion per year

30k at $70k = 2.1 billion per year

30k at $80k = 2.4 billion per year

30k at $90k = 2.7 billion per year

If you do the math and apply realistically conservative numbers it all adds up to a
BO value of $45-65